191.70
0.36 (0.19%)
| Previous Close | 191.33 |
| Open | 191.35 |
| Volume | 616,399 |
| Avg. Volume (3M) | 1,349,876 |
| Market Cap | 34,792,644,608 |
| Price / Earnings (TTM) | 25.19 |
| Price / Earnings (Forward) | 16.45 |
| Price / Sales | 2.37 |
| Price / Book | 5.14 |
| 52 Weeks Range | |
| Earnings Date | 12 Feb 2025 - 17 Feb 2025 |
| Profit Margin | 9.17% |
| Operating Margin (TTM) | 14.84% |
| Diluted EPS (TTM) | 7.83 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | -5.90% |
| Total Debt/Equity (MRQ) | 200.26% |
| Current Ratio (MRQ) | 0.810 |
| Operating Cash Flow (TTM) | 2.58 B |
| Levered Free Cash Flow (TTM) | 2.00 B |
| Return on Assets (TTM) | 5.11% |
| Return on Equity (TTM) | 22.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | IQVIA Holdings, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.92% |
| % Held by Institutions | 94.53% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 276.00 (Redburn Atlantic, 43.98%) | Buy |
| Median | 255.00 (33.02%) | |
| Low | 212.00 (Baird, 10.59%) | Hold |
| Average | 253.80 (32.40%) | |
| Total | 14 Buy, 1 Hold | |
| Avg. Price @ Call | 207.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stephens & Co. | 20 Dec 2024 | 250.00 (30.42%) | Buy | 197.27 |
| B of A Securities | 13 Dec 2024 | 235.00 (22.59%) | Buy | 199.06 |
| Truist Securities | 12 Dec 2024 | 261.00 (36.15%) | Buy | 200.37 |
| 04 Nov 2024 | 265.00 (38.24%) | Buy | 210.19 | |
| Baird | 11 Dec 2024 | 212.00 (10.59%) | Hold | 201.07 |
| 01 Nov 2024 | 223.00 (16.33%) | Hold | 209.16 | |
| RBC Capital | 11 Dec 2024 | 270.00 (40.85%) | Buy | 201.07 |
| 04 Dec 2024 | 270.00 (40.85%) | Buy | 203.17 | |
| Leerink Partners | 19 Nov 2024 | 248.00 (29.37%) | Buy | 191.33 |
| JP Morgan | 05 Nov 2024 | 240.00 (25.20%) | Buy | 212.87 |
| 23 Oct 2024 | 279.00 (45.54%) | Buy | 228.31 | |
| Morgan Stanley | 04 Nov 2024 | 265.00 (38.24%) | Buy | 210.19 |
| BTIG | 01 Nov 2024 | 260.00 (35.63%) | Buy | 209.16 |
| Barclays | 01 Nov 2024 | 255.00 (33.02%) | Buy | 209.16 |
| 15 Oct 2024 | 260.00 (35.63%) | Buy | 232.98 | |
| Deutsche Bank | 01 Nov 2024 | 265.00 (38.24%) | Buy | 209.16 |
| Goldman Sachs | 01 Nov 2024 | 250.00 (30.42%) | Buy | 209.16 |
| TD Cowen | 01 Nov 2024 | 255.00 (33.02%) | Buy | 209.16 |
| Redburn Atlantic | 14 Oct 2024 | 276.00 (43.98%) | Buy | 233.22 |
| Evercore ISI Group | 08 Oct 2024 | 265.00 (38.24%) | Buy | 226.72 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Nov 2024 | Announcement | IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024 |
| 31 Oct 2024 | Announcement | IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day |
| 15 Oct 2024 | Announcement | IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024 |
| 02 Oct 2024 | Announcement | IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™ |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |